Blco.K
BLCO.K operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to customers in the healthcare sector.
Business. BLCO.K operates in the Medical Equipment, Supplies & Distribution industry within the broader Healthcare Services & Equipment sector. The company generates revenue primarily through the sale of products. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Analyst recommendations
13 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
This is the first analysis for Bausch + Lomb Corp (BLCO.K), meaning there is no prior basis for computing material changes in the company's profile. Consequently, the current snapshot serves as the initial baseline for tracking the firm's financial and ownership dynamics. The most notable activity involves a series of new institutional holdings detected as of the end of the first quarter of 2026. Multiple investors initiated positions in the stock, with filings reflecting share acquisitions ranging from small stakes to more significant blocks. For instance, one investor added 1,224,603 shares valued at approximately $19.5 million, while another acquired 845,914 shares worth roughly $13.5 million. Additional notable additions include positions of 453,179 shares valued at $7.2 million, 292,886 shares valued at $4.7 million, and 85,779 shares valued at $1.4 million. A smaller position of 22,274 shares, valued at $0.3 million, was also recorded as of June 30, 2024. These entries indicate a broadening of the shareholder base during this period. Bausch + Lomb currently has 13 top holders and one officer on record, with no analyst coverage or index membership noted in this initial assessment. The influx of new institutional capital suggests growing interest in the company, providing a foundation for future monitoring of ownership concentration and potential market sentiment shifts.
Signals & dispatch
Composite-score breakdown
Synthesis
BLCO.K operates in the Medical Equipment, Supplies & Distribution industry within the broader Healthcare Services & Equipment sector. The company generates revenue primarily through the sale of products. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
The company's capital structure is characterized by a debt-to-equity ratio of 0.79, indicating a moderate level of leverage. The liquidity position is marked by a current ratio of 1.55, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -280 million USD, which may indicate a need for external financing or operational adjustments.
Profitability metrics show a return on equity of -5.58% and a return on assets of -2.57%, both of which are below the industry median, indicating that the company is underperforming in terms of generating returns for its shareholders and assets. The operating margin is 2.1%, which is also below the industry median, suggesting that the company is not as efficient in converting revenue into operating profit as its peers.
The company's revenue is concentrated in a single segment, with no disclosed geographic diversification, which may expose the company to higher risk if the segment or region experiences a downturn. The company's growth trajectory is uncertain, with no significant revenue growth reported in the latest financial period.
The company faces a risk of dilution, although the risk is currently assessed as low. The company's liquidity risk is medium, as indicated by the risk assessment, and the company has a negative net cash position after subtracting total debt. Recent events, such as the company's net loss of 360 million USD, may impact investor sentiment and the company's ability to attract capital.
This is the first analysis for Bausch + Lomb Corp (BLCO.K), meaning there is no prior basis for computing material changes in the company's profile. Consequently, the current snapshot serves as the initial baseline for tracking the firm's financial and ownership dynamics. The most notable activity involves a series of new institutional holdings detected as of the end of the first quarter of 2026. Multiple investors initiated positions in the stock, with filings reflecting share acquisitions ranging from small stakes to more significant blocks. For instance, one investor added 1,224,603 shares valued at approximately $19.5 million, while another acquired 845,914 shares worth roughly $13.5 million. Additional notable additions include positions of 453,179 shares valued at $7.2 million, 292,886 shares valued at $4.7 million, and 85,779 shares valued at $1.4 million. A smaller position of 22,274 shares, valued at $0.3 million, was also recorded as of June 30, 2024. These entries indicate a broadening of the shareholder base during this period. Bausch + Lomb currently has 13 top holders and one officer on record, with no analyst coverage or index membership noted in this initial assessment. The influx of new institutional capital suggests growing interest in the company, providing a foundation for future monitoring of ownership concentration and potential market sentiment shifts.
- The company has a moderate level of leverage with a debt-to-equity ratio of 0.79.
- The company's profitability metrics are below the industry median, indicating underperformance.
- The company's revenue is concentrated in a single segment, which may increase risk.
- The company's liquidity position is medium, with a current ratio of 1.55.
- The company has a negative free cash flow, which may require external financing.
- The company's risk of dilution is currently assessed as low.
- margin_outlook_rationale: The company's operating margin is below the industry median, indicating potential inefficiencies in converting revenue into profit.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,80 |
| Revenue | —no estimate | —no estimate | 5,5B USD |
| Operating income | —no estimate | —no estimate | 732,5M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- BLCO.K Market data — financials · 2026-05-27
- Bausch + Lomb Corp Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,01 %$16M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Leadership
- Brent L. SaundersChairman of the Board, Chief Executive Officer
Insider activity
- President, Surgical · Common Shares, No Par ValueOther 1 008 @ $15,08$15K · 2026-06-12
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director · Common Shares, No Par ValueOther 15 842 @ $15,78$250K · 2026-05-26
- Director, Chairman of the Board and CEO · Common Shares, No Par ValueOther 2 886 @ $15,92$46K · 2026-05-22
- SVP, Controller and CAO · Common Shares, No Par ValueOther 8 673 @ $16,00$139K · 2026-05-05
- EVP and CFO · Common Shares, No Par ValueOther 63 938 @ $16,00$1,0M · 2026-05-05
- EVP of R&D and CMO · Common Shares, No Par ValueOther 13 664 @ $16,00$219K · 2026-05-05
- President, Surgical · Common Shares, No Par ValueOther 11 970 @ $16,00$192K · 2026-05-05
- Director · Common Shares, No Par ValueOther 1 415 @ $15,90$22K · 2026-04-30
- Director · Common Shares, No Par ValueOther 1 611 @ $15,90$26K · 2026-04-30
- Director · Common Shares, No Par ValueOther 1 375 @ $15,90$22K · 2026-04-30
- Director · Common Shares, No Par ValueOther 1 375 @ $15,90$22K · 2026-04-30
- President, GPIC · Common Shares, No Par ValueOther 4 216 @ $15,82$67K · 2026-04-24
- EVP & Chief Legal Officer · Common Shares, No Par ValueOther 15 806 @ $15,82$250K · 2026-04-24
- Director, CEO and Chairman of the Board · Common Shares, No Par ValueOther 14 700 · 2026-03-06
- EVP & Chief Legal Officer · Common Shares, No Par ValueBought 14 600 @ $17,15$250K · 2026-03-06
- EVP & Chief Legal Officer · Common Shares, No Par ValueOther 14 600 · 2026-03-06
- EVP and CFO · Common Shares, No Par ValueBought 4 000 @ $17,13$69K · 2026-03-06
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 8.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 4.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -0.4%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 6.5%Derived (calculated)
- Net margin (FY 2025-12-31): -7.1%Derived (calculated)
- Return on equity (FY 2025-12-31): -5.6%Derived (calculated)
- Return on assets (FY 2025-12-31): -2.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.55xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.16xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 19.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 25.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -13.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -13.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -13.6%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 5.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -30.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 22.0%Derived (calculated)
- Net income (annual): USD -360MSEC XBRL filing
- Long-term debt (annual): USD 5.05BSEC XBRL filing
- Total assets (annual): USD 14.02BSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Capex (annual): USD 349MSEC XBRL filing
- Pre-tax income (annual): USD -317MSEC XBRL filing
- Current liabilities (annual): USD 1.92BSEC XBRL filing